These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22415185)

  • 1. [The Brazilian pharmaceutical industry and foreign trade: is there evidence of regressive specialization?].
    Mota FB; Cassiolato JE; Gadelha CA
    Cad Saude Publica; 2012 Mar; 28(3):527-36. PubMed ID: 22415185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Economic determinants of the demand for importation of pharmacochemical and pharmaceutical products].
    Santos AMAD; Tejada CAO; Jacinto PA
    Cad Saude Publica; 2017 Sep; 33(9):e00087916. PubMed ID: 28977272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding drug access in Brazil: lessons for Latin America and Canada.
    Cohen JC
    Can J Public Health; 2006; 97(6):I15-8. PubMed ID: 17203728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections.
    Lindsley CW
    ACS Chem Neurosci; 2019 Mar; 10(3):1115. PubMed ID: 30889957
    [No Abstract]   [Full Text] [Related]  

  • 6. Brazilian pharmaceutical diplomacy: social democratic principles versus soft power interests.
    Flynn M
    Int J Health Serv; 2013; 43(1):67-89. PubMed ID: 23527455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Study of Comparative Advantage and Intra-Industry Trade in the Pharmaceutical Industry of Iran.
    Yusefzadeh H; Rezapour A; Lotfi F; Ebadifard Azar F; Nabilo B; Abolghasem Gorji H; Hadian M; Shahidisadeghi N; Karami A
    Glob J Health Sci; 2015 Apr; 7(6):295-307. PubMed ID: 26153184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From transit hub to major supplier of illicit cigarettes to Argentina and Brazil: the changing role of domestic production and transnational tobacco companies in Paraguay between 1960 and 2003.
    Iglesias RM; Gomis B; Carrillo Botero N; Shepherd P; Lee K
    Global Health; 2018 Nov; 14(1):111. PubMed ID: 30454015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of parallel trade on pharmaceutical firm's profits: rise or fall?
    Guo S; Hu B; Zhong H
    Eur J Health Econ; 2013 Apr; 14(2):345-55. PubMed ID: 22286662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How parallel trade affects drug policies and prices in Canada and the United States.
    Hollis A; Ibbott P
    Am J Law Med; 2006; 32(2-3):193-217. PubMed ID: 16927610
    [No Abstract]   [Full Text] [Related]  

  • 12. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 14. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
    Faunce TS; Tomossy GF
    Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
    Sykes AO
    Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
    [No Abstract]   [Full Text] [Related]  

  • 16. Can complexity be commercialized?
    Mack GS
    Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456
    [No Abstract]   [Full Text] [Related]  

  • 17. Sales from licensed and acquired products to increase by 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Jun; 8(6):443. PubMed ID: 19483704
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing the impact of global price interdependencies.
    Richter A
    Pharmacoeconomics; 2008; 26(8):649-59. PubMed ID: 18620459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New 2017 Data and Statistics for Pharmaceutical Products.
    Lindsley CW
    ACS Chem Neurosci; 2018 Jul; 9(7):1518-1519. PubMed ID: 30016875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.